Baird Medical Investment (NASDAQ:BDMD) Upgraded to Hold at Wall Street Zen

Baird Medical Investment (NASDAQ:BDMD) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Baird Medical Investment in a research report on Tuesday, January 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Baird Medical Investment Stock Up 8.6%

BDMD stock opened at $2.40 on Friday. The company has a fifty day moving average price of $1.56 and a 200-day moving average price of $1.67. Baird Medical Investment has a 52-week low of $0.76 and a 52-week high of $7.26.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of Baird Medical Investment by 59.7% in the 2nd quarter. Geode Capital Management LLC now owns 25,442 shares of the company’s stock worth $93,000 after purchasing an additional 9,511 shares during the period. Jane Street Group LLC bought a new stake in shares of Baird Medical Investment in the 2nd quarter valued at $142,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Baird Medical Investment during the third quarter worth $99,000. Institutional investors own 19.78% of the company’s stock.

Baird Medical Investment Company Profile

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.